Free tool
FAERS Monitor: Auvi-Q
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 201739 or its brand name (Auvi-Q, Epinephrine). Reports on generic versions are filed under their own applications.
Reports
43,337
Serious
26,523
61% of reports
Hospitalization
14,066
Death reported
3,554
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective4,644
- headache3,108
- sinusitis2,928
- fatigue2,823
- product dose omission issue2,800
- pain2,512
- covid-192,434
- dyspnoea2,295
- nausea2,255
- off label use2,096
- pneumonia2,078
- inappropriate schedule of product administration1,794
- nasopharyngitis1,686
- pyrexia1,670
- cough1,598
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 133 |
| 2005 | 118 |
| 2006 | 136 |
| 2007 | 166 |
| 2008 | 194 |
| 2009 | 269 |
| 2010 | 261 |
| 2011 | 702 |
| 2012 | 425 |
| 2013 | 316 |
| 2014 | 450 |
| 2015 | 693 |
| 2016 | 1,121 |
| 2017 | 1,606 |
| 2018 | 2,536 |
| 2019 | 3,428 |
| 2020 | 6,560 |
| 2021 | 3,969 |
| 2022 | 3,701 |
| 2023 | 3,884 |
| 2024 | 4,553 |
| 2025 | 4,798 |
| 2026 | 3,315 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,010,822 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sinusitisSignal | 2,928 | 14.2 | 13.7 | 35,185 |
| covid-19Signal | 2,434 | 6.8 | 6.6 | 12,001 |
| inappropriate schedule of product administrationSignal | 1,794 | 4.9 | 4.7 | 5,505 |
| product dose omission issueSignal | 2,800 | 4.7 | 4.5 | 8,071 |
| nasopharyngitisSignal | 1,686 | 4.5 | 4.3 | 4,538 |
| pneumoniaSignal | 2,078 | 3.1 | 3.0 | 3,035 |
| coughSignal | 1,598 | 2.8 | 2.6 | 1,828 |
| headacheSignal | 3,108 | 2.4 | 2.3 | 2,636 |
| pyrexiaSignal | 1,670 | 2.3 | 2.2 | 1,308 |
| pain | 2,512 | 2.0 | 1.9 | 1,266 |
| dyspnoea | 2,295 | 2.0 | 1.9 | 1,124 |
| fatigue | 2,823 | 1.8 | 1.7 | 963 |
| drug ineffective | 4,644 | 1.7 | 1.7 | 1,463 |
| nausea | 2,255 | 1.4 | 1.3 | 248 |
| off label use | 2,096 | 1.2 | 1.1 | 49 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.